Diamedica Has Been Quietly Running Its Trials. Monday, the Silence Ends.

Diamedica Therapeutics Inc (DMAC) reports fourth-quarter 2025 earnings after market close on March 30, 2026, with analysts expecting continued losses as the clinical-stage biopharmaceutical company advances its stroke treatment pipeline. With the stock trading below most key moving averages and technical signals deteriorating sharply, investors will be watching for updates on clinical trial progress and cash runway that could justify the bullish analyst price targets or validate mounting technical concerns.

Part 1: Earnings Preview

Diamedica Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological diseases, particularly its lead candidate DM-199 for acute ischemic stroke and chronic kidney disease. The company operates primarily in the biotechnology sector, with its value proposition centered on advancing its pipeline through clinical trials.

DMAC is scheduled to report fourth-quarter 2025 results after the close on March 30, 2026. Analysts expect an EPS loss of -$0.17, with one analyst covering the quarter. The company most recently reported a loss of -$0.17 per share for the third quarter of 2025. Compared to the same quarter last year (Q4 2024), when DMAC posted a loss of -$0.18 per share, the current estimate represents a 5.56% improvement year-over-year, suggesting modestly narrowing losses.

Three key themes define this earnings story:

Clinical Trial Progress and Regulatory Milestones: As a clinical-stage company, any updates on DM-199's development timeline, patient enrollment, or regulatory interactions will be critical. Investors will scrutinize commentary on the stroke treatment program's advancement and whether the company remains on track for key data readouts.

Cash Position and Runway: With consistent quarterly losses averaging around $0.17-$0.18 per share, the company's cash burn rate and available capital will be paramount. Management's guidance on how long current resources can fund operations without additional financing will heavily influence investor sentiment.

Full-Year 2026 Outlook: Analysts project losses widening to -$0.74 per share for full-year 2026 versus -$0.66 in 2025, representing a 12.12% increase in losses. Any commentary on cost management, trial expenses, or strategic priorities that could affect this trajectory will be closely monitored.

Part 2: Historical Earnings Performance

DMAC has demonstrated a mixed earnings track record over the past four quarters, with two quarters meeting estimates exactly and two quarters missing expectations. The company's most recent quarter (Q3 2025) saw a -13.33% miss, reporting a loss of -$0.17 versus the -$0.15 estimate. This followed two consecutive quarters (Q2 and Q1 2025) where the company met analyst expectations precisely at -$0.18 per share.

Looking back to Q4 2024, DMAC posted a -5.88% miss, reporting -$0.18 against a -$0.17 estimate. The pattern reveals that when DMAC misses, the magnitude tends to be relatively modest (in the 5-14% range), but the company has struggled to deliver positive surprises. The consistency of losses in the $0.15-$0.18 range reflects the predictable cash burn of a clinical-stage biotech, though the recent Q3 miss suggests potential variability in quarterly expenses or trial-related costs that could make estimates more challenging to hit precisely.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

DMAC typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

DMAC exhibits significant post-earnings volatility, with an average absolute Day 0 move of 4.18% and Day +1 move of 7.13%. The most dramatic recent reaction came after the August 2025 report, when the stock surged 13.97% on Day 0 and extended gains to 14.94% by Day +1. Conversely, the November 2025 report triggered a sharp -14.10% decline on Day +1 despite minimal Day 0 movement.

The historical pattern shows Day +1 moves consistently exceed Day 0 moves (7.13% vs. 4.18% on average), which aligns with after-hours reporting—the market's full reaction materializes in the following session. Intraday ranges are substantial, averaging 8.29% on Day 0 and 11.84% on Day +1, indicating considerable two-way volatility as investors digest clinical updates and cash position commentary. Recent quarters show heightened volatility compared to 2024, with the last two reports producing Day +1 moves exceeding 13% in absolute terms.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 21.31% (±$1.45) for the April expiration, which is substantially higher than the historical average Day +1 move of 7.13%. This elevated implied volatility suggests options traders are anticipating a more significant reaction than typical, possibly reflecting heightened uncertainty around clinical trial updates or financing needs that could drive outsized price action.

Part 3: What Analysts Are Saying

Analysts maintain a strongly bullish stance on DMAC, with the stock earning an average recommendation of 4.67 out of 5.00—firmly in Strong Buy territory. The consensus includes 5 Strong Buy ratings and 1 Hold, with no Sell recommendations among the six analysts covering the stock.

The analyst community's sentiment has remained unchanged over the past month, with the rating distribution holding steady at 5 Strong Buys and 1 Hold. This stability suggests analysts are maintaining conviction in their bullish thesis despite the stock's recent technical weakness.

The average price target of $15.50 implies 128% upside from the current price of $6.79, with individual targets ranging from a low of $11.00 (62% upside) to a high of $25.00 (268% upside). This wide target range reflects differing views on the probability and timeline of clinical success, but even the most conservative target suggests substantial appreciation potential if the company's stroke treatment program advances successfully.

Part 4: Technical Picture

The Barchart Technical Opinion has deteriorated sharply, currently showing a 24% Sell signal—a significant weakening from the 56% Buy signal just one month ago and down from 8% Sell last week. This rapid shift reflects mounting technical pressure as the stock has broken below multiple support levels.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum has turned negative, suggesting continued downside pressure in the immediate sessions ahead
• Medium-term (Hold): Neutral reading suggests the intermediate trend is in transition, with neither bulls nor bears in clear control
• Long-term (Hold): Neutral signal reflects an absence of strong directional conviction in the longer-term trend structure

Trend Characteristics: The current environment shows Minimum strength with Average direction, indicating a weak and indecisive trend that lacks conviction—a challenging technical backdrop heading into a potentially volatile earnings event.

DMAC is trading at $6.79, positioned below the 5-day ($6.94), 10-day ($6.99), 20-day ($7.32), 50-day ($7.90), and 100-day ($7.91) moving averages, but above the 200-day moving average ($6.72). This configuration shows the stock in a clear downtrend across all short- and intermediate-term timeframes, with only the long-term 200-day average providing support.

The $6.72 level (200-day moving average) represents critical support—a break below would signal long-term trend deterioration and could trigger additional technical selling. Resistance is stacked overhead at $6.94-$6.99 (5/10-day averages), with more substantial resistance at $7.32 (20-day). The overall technical setup is cautionary heading into earnings, as the stock enters the event from a position of weakness with deteriorating momentum indicators. However, the substantial disconnect between the current price and analyst targets ($15.50 average) suggests that a positive clinical update or encouraging cash runway commentary could trigger a sharp reversal, particularly given the options market's expectation of a 21% move.